Vivimed gets CCI nod to products sale deal with Clariant

Image
Press Trust of India New Delhi
Last Updated : Dec 24 2015 | 12:07 PM IST
Drug firm Vivimed Labs today said the Competition Commission has given its approval to a deal with Clariant Chemicals India to sell some products in its speciality chemicals division.
"The Competition Commission of India vide its letter dated December 21, 2015, has granted its approval, under Section 31(1) of the Competition Act, 2002, with respect to the proposed acquisition of certain products in Speciality Chemicals division of the company by Clariant India Ltd," Vivimed Labs said in a BSE filing.
The order of the CCI will be received in due course of time, the company said, adding that other permits and approvals required for the deal are awaited and expected shortly.
In September, Vivimed had signed a pact for sale of some of products in its speciality chemicals division to Clariant Chemicals India at an enterprise value of Rs 380 crore.
The company has signed a definitive agreement for the transfer and sale of identified products within speciality division to company Clariant AGs subsidiary Clariant Chemicals India Ltd.
Vivimed Labs shares were trading 1.14 per cent up at Rs 432.90 apiece on the BSE in the morning trade.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Dec 24 2015 | 12:07 PM IST

Next Story